Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26474537 | 0.99 | MDM2 (0.46) | TLR2MDM2MDM4TP53TNF | |
| SCHEMBL19367953 | 0.95 | TLR2 (0.43) | TLR2MDM2MDM4TP53TNF | |
| SCHEMBL17760889 | 0.93 | TLR2 (0.46) | TLR2MDM2MDM4TP53TNF | |
| SCHEMBL18161126 | 0.90 | TLR2 (0.43) | TLR2MDM2MDM4TP53 | |
| SCHEMBL18161129 | 0.89 | TLR2 (0.44) | TLR2MDM2MDM4TP53 | |
| SCHEMBL15893676 | 0.89 | TLR2 (0.45) | TLR2MDM2MDM4TP53 | |
| SCHEMBL15761355 | 0.87 | MDM4 (0.44) | MDM2MDM4TP53 | |
| SCHEMBL17751704 | 0.87 | MDM4 (0.43) | TLR2MDM2MDM4TP53 | |
| SCHEMBL8242447 | 0.86 | MDM4 (0.43) | TLR2MDM2MDM4TP53 | |
| SCHEMBL31591662 | 0.86 | MDM2 (0.42) | TLR2MDM2MDM4TP53HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-9856292-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160137696-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137696-A1 | Immunomodulators | CD74, ICOS, HAVCR2 | TLR2 91/4885MDM2 967/4885MDM4 672/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | TLR2 91/4885MDM2 967/4885MDM4 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.